External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Equity Bottom-Up

<ul><li>YSB specializes in providing digital solutions in China’s outside-of-hospital pharmaceutical circulation market.</li><li>According to Frost &amp; Sullivan (F&amp;S), the Company is the largest digital pharmaceutical platform serving businesses outside of hospitals in China, taking a market share of 21.0% in 2022 in terms of GMV (gross merchandise volume).</li><li>YSB’s business model mainly includes Online Marketplace and Self-operation Business (including Targeted Product Launch Business).</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

YSB specializes in providing digital solutions in China’s outside-of-hospital pharmaceutical circulation market.According to Frost &amp; Sullivan (F&amp;S), the Company is the largest digital pharmaceutical platform serving businesses outside of hospitals in China, taking a market share of 21.0% in 2022 in terms of GMV (gross merchandise volume).YSB’s business model mainly includes Online Marketplace and Self-operation Business (including Targeted Product Launch Business).Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

YSB (9885 HK) – Digitalizing Outside-Of-Hospital Pharmaceutical Circulation Market in China

APAC IPOs & Placements, Aequitas Research

Clarence Chu

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

WuXi XDC Cayman  / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/wuxi-xdc-cayman-inc" target="_blank" data-smartkarma-citation="entities:39917:1" rel="noopener">WuXi XDC Cayman Inc (1877628D HK)</a> is looking to raise &gt;US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are Morgan Stanley, Goldman Sachs, and JP Morgan.</li>
<li>WuXi XDC Cayman (WXDC) is a contract research, development, and manufacturing organization (CRDMO) focused on the global antibody drug conjugates (ADC) and broader bioconjugate market providing integrated and end-to-end services.</li>
<li>As per Frost &amp; Sullivan (F&amp;S), the firm was the second largest CRDMO for ADCs and other bioconjugates globally in terms of FY22 sales.</li>
</ul>



WuXi XDC Cayman Inc (1877628D HK) is looking to raise &gt;US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are Morgan Stanley, Goldman Sachs, and JP Morgan.
WuXi XDC Cayman (WXDC) is a contract research, development, and manufacturing organization (CRDMO) focused on the global antibody drug conjugates (ADC) and broader bioconjugate market providing integrated and end-to-end services.
As per Frost &amp; Sullivan (F&amp;S), the firm was the second largest CRDMO for ADCs and other bioconjugates globally in terms of FY22 sales.


Guangdong Archealth Health Industry Group / Equity Capital Markets

Guangdong Archealth Health Industry Group

<ul>
<li>
<a href="https://www.smartkarma.com/entities/guangdong-archealth-health-industry-group" target="_blank" data-smartkarma-citation="entities:39926:1" rel="noopener">Guangdong Archealth Health Industry Group (GAHI HK)</a> is looking to raise around US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are CICC and ABCI.</li>
<li>Guangdong Archealth Health Industry Group (GAHI) is a digital health management provider.</li>
<li>According to F&amp;S, the firm ranked first in the weight management industry and first in the digital weight management industry in China as per 2022 sales.</li>
</ul>



Guangdong Archealth Health Industry Group (GAHI HK) is looking to raise around US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are CICC and ABCI.
Guangdong Archealth Health Industry Group (GAHI) is a digital health management provider.
According to F&amp;S, the firm ranked first in the weight management industry and first in the digital weight management industry in China as per 2022 sales.


Guangdong Archealth Health Industry Group Tearsheet

Silver Dragon Water Supply Group / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/silver-dragon-water-supply-group" target="_blank" data-smartkarma-citation="entities:39898:1" rel="noopener">Silver Dragon Water Supply Group (2210081D CH)</a> is looking to raise at least US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are HSBC and Huatai International.</li>
<li>Silver Dragon Water Supply Group (SDW) is principally engaged in the supply of tap water, raw water and pipeline direct drinking water in China.</li>
<li>As per Frost &amp; Sullivan (F&amp;S), the firm had the largest water pipeline network in terms of water pipeline length among all water supply companies in China in 2022.</li>
</ul>



Silver Dragon Water Supply Group (2210081D CH) is looking to raise at least US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are HSBC and Huatai International.
Silver Dragon Water Supply Group (SDW) is principally engaged in the supply of tap water, raw water and pipeline direct drinking water in China.
As per Frost &amp; Sullivan (F&amp;S), the firm had the largest water pipeline network in terms of water pipeline length among all water supply companies in China in 2022.


Silver Dragon Water Supply Group Pre-IPO Tearsheet

<ul>
<li>
<a href="https://www.smartkarma.com/entities/qiniu-limited" target="_blank" data-smartkarma-citation="entities:39897:1" rel="noopener">Qiniu Limited (1045102D CH)</a> is looking to raise about US$200m in its upcoming Hong Kong IPO.</li>
<li>Qiniu Limited (Qiniu) is a one-stop scenario-based intelligent audiovisual service provider.</li>
<li>According to iResearch, the firm is the third largest audiovisual platform as a service (PaaS) provider in China in terms of FY22 revenue, with a market share of 5.7%. </li>
</ul>



Qiniu Limited (1045102D CH) is looking to raise about US$200m in its upcoming Hong Kong IPO.
Qiniu Limited (Qiniu) is a one-stop scenario-based intelligent audiovisual service provider.
According to iResearch, the firm is the third largest audiovisual platform as a service (PaaS) provider in China in terms of FY22 revenue, with a market share of 5.7%. 


China

YSB Inc. operates as a digital pharmaceutical platform outside of hospitals in China.. The Company provides outside of hospital pharmaceutical circulation services. YSB mainly offers services to pharmaceutical companies, distributors, vendors, pharmacies, primary healthcare institutions, and others.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

YSB (9885 HK)

YSB (9885 HK) – Digitalizing Outside-Of-Hospital Pharmaceutical Circulation Market in China

YSB’s business model mainly includes Online Marketplace and Self-operation Business (including Targeted Product Launch Business).

CMB International

WuXi XDC Cayman Pre-IPO Tearsheet

WuXi XDC Cayman Inc (1877628D HK) is looking to raise >US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are Morgan Stanley,...

Clarence Chu

Guangdong Archealth Health Industry Group Tearsheet

Guangdong Archealth Health Industry Group (GAHI HK) is looking to raise around US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal...

Clarence Chu

Silver Dragon Water Supply Group Pre-IPO Tearsheet

Silver Dragon Water Supply Group (2210081D CH) is looking to raise at least US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are...

Clarence Chu

Qiniu Pre-IPO Tearsheet

Qiniu Limited (1045102D CH) is looking to raise about US$200m in its upcoming Hong Kong IPO. Qiniu Limited (Qiniu) is a one-stop scenario-based...

Clarence Chu

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)